FindTrial
Sign In

TQB3909 tablets

DRUG6 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

Advanced Breast CancerAdvanced Malignant NeoplasmAdvanced Malignant TumorHematologic MalignancyMyelofibrosisRelapsed/Refractory Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymppho

Phase 1

A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors
NCT04975204
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Malignant Tumor
Start: 2022-02-18End: 2024-08-31Target: 126Updated: 2022-03-07
A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer
NCT05775575
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Breast Cancer
Start: 2023-03-02End: 2023-12-31Target: 65Updated: 2023-03-20
A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets
NCT06165822
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Malignant Neoplasm
Start: 2023-12-31End: 2024-03-31Target: 40Updated: 2023-12-12
A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy
Not yet recruitingNCT06211751
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Hematologic Malignancy
Start: 2024-01-31End: 2026-06-30Target: 208Updated: 2024-01-18
A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)
TerminatedNCT06245941
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Myelofibrosis
Start: 2024-05-13End: 2025-12-30Updated: 2026-01-05

Phase 3

A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Not yet recruitingNCT07753369
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymppho
Start: 2026-08-01End: 2030-12-01Target: 128Updated: 2026-08-11

Related Papers

BCL-2 inhibitor TQB3909 combined with JAK inhibitors in patients with intermediate- or high-risk myelofibrosis: A two-cohort, open-label, Phase ib/II, multicenter study
Blood2025-11-03
Monitoramento do Horizonte Tecnológico (MHT) de Inibidores de Janus Quinase (JAKi) para o Tratamento de Mielofibrose
Epidemiologia e Serviços de Saúde2025-01-01